@article{b98a37bd812a40f9beadca130753ea4a,
title = "Pimavanserin tartrate: A 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders",
abstract = "Background: Pimavanserin tartrate is the first 5-HT2A inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia. Pimavanserin is also being evaluated as a possible anti-insomnia drug. Objective: To discuss the potential of pimavanserin to fill multiple therapeutic needs. Methods: The problems with currently approved antipsychotics and sleep agents are explored to highlight how pimavanserin might address some longstanding issues in the treatment of psychosis and insomnia. Results/conclusions: In Phase II clinical trials, pimavanserin seemed to be safe, well-tolerated and efficacious in treating L-dopa-induced psychosis without worsening motor symptoms. Pimavanserin also potentiated the therapeutic effects of low-dose risperidone, reduced haloperidol-induced akathisia, and increased slow-wave sleep in older individuals.",
keywords = "5-HT, Parkinson's Disease, antipsychotic, inverse agonist, pimavanserin, psychosis, schizophrenia",
author = "Atheir Abbas and Roth, \{Bryan L.\}",
year = "2008",
month = dec,
doi = "10.1517/14656560802532707",
language = "English (US)",
volume = "9",
pages = "3251--3259",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "18",
}